Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations
December 11, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia
November 30, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
November 18, 2020 19:02 ET
|
Prevail Therapeutics
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
November 13, 2020 07:00 ET
|
Prevail Therapeutics
Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of...
Prevail Therapeutics to Present at Upcoming Investor Conferences
November 10, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
November 02, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease
October 27, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at Upcoming Investor Conferences
September 25, 2020 17:21 ET
|
Prevail Therapeutics
NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 18, 2020 15:04 ET
|
Prevail Therapeutics
NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors
September 10, 2020 07:00 ET
|
Prevail Therapeutics
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...